NTRK1 and adrenal cortex carcinoma: This urges the need for better therapeutic options but while targeting receptor tyrosine kinases was hailed as game changing in other solid cancers, the trials with e.g. VEGFR and IGFR inhibitors in ACC were disappointing (14).